Euan Reid

@euanreid.pharmsky.app

Pharmacist 🏴󠁧󠁢󠁳󠁣󠁴󠁿 #Pharmsky

Are tocilizumab & sarilumab equally effective for severe COVID-19? A new @natcomms.nature.com study of 10k+NHS hospital patients in England 🏴󠁧󠁢󠁥󠁮󠁧󠁿 & Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿 shows no difference in 28-day mortality or time to discharge. Both IL-6 inhibitors are equally effective options www.nature.com/articles/s41...

Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and Scotland - Nature Communications

Using electronic health record databases in England and Scotland, this study compared tocilizumab and sarilumab in over 10,000 hospitalised COVID-19 patients and found no meaningful difference in surv...

nature.com

The Court of Appeal has upheld findings that pharma firms illegally jacked up the price of lifesaving hydrocortisone tablets from <£1 to >£70 per pack. Annual NHS spending surged from £500k to £80m+. A clear warning against price-gouging. #Pharmsky www.gov.uk/government/n...

Court upholds CMA findings that firms charged excessive and unfair prices for lifesaving NHS-funded medicine

The Court of Appeal has confirmed that firms broke the law by charging excessive and unfair prices for hydrocortisone tablets over a decade.

gov.uk

🚨NEW – GPs in Scotland Read the blog from SGPC deputy chair Dr Chris Black on GP IT reprovisioning covering: 👉Action being taken by SGPC on concerns raised 👉Background to the implementation of Vision 👉Lessons to be learned Link 👇 bmascotland.home.blog/2026/07/20/g...

GP IT reprovisioning: practices need more than promises

As GPs, I don’t need to tell you how vital it is we have reliable IT systems that work for us and patients. Put simply, clinical systems in general practice are not background machinery. They are t…

bmascotland.home.blog

Some medications can make it harder to cope with extreme heat. 🌡 We're pleased to see Heal Canada adapt our evidence-informed article on medications & heat waves for the June issue of E3 Advocacy, helping this important information reach even more Canadians (pp. 108–112). 📚 tinyurl.com/4cbun8jf

BildBildBildBild

A study in BMC Medicine finds that breastfeeding up to 12 months of age is associated with reduced infection burden and inflammation, as well as differences in metabolomic biomarkers and lipids, mediating much of these beneficial effects. #MedSky

The protective effect of breastfeeding on infant inflammation: a mediation analysis of the plasma lipidome and metabolome - BMC Medicine

Background Inflammation has long-term health impacts across the life course. Breastfeeding substantially reduces inflammation risk, but key pathways, including the extent that this is due to protection against early life infection, are poorly understood. We aimed to investigate the relationships between breastfeeding, inflammation, and infection burden, and to determine the extent to which metabolomic and lipidomic profiles associated with breastfeeding mediate these health outcomes. Methods We utilised data from the Barwon Infant Study (BIS), a longitudinal birth cohort in Victoria, Australia. Infants (n = 889) with available breastfeeding (categorised as yes/no) clinical, metabolomic, and Lipidomic data at 6 and/or 12 months were included (n = 793 at 6 months, n = 734 at 12 months). Inflammation, measured via glycoprotein acetyls (GlycA), at 6 and 12 months and infection burden, including parent-reported and medically attended infections assessed through standardised 3-monthly questionnaires were used as outcomes. Results Any breastfeeding, regardless of supplementary feeding, was associated with lower inflammation, fewer infections, and significant, potentially beneficial changes in metabolomic and lipidomic markers, particularly plasmalogens. There was evidence of bidirectional mediation: metabolomic biomarkers and lipids mediated breastfeeding’s effects on inflammation, while inflammation partly mediated breastfeeding’s impact on certain metabolites and lipids. Conclusions These findings highlight pathways through which breastfeeding reduces inflammation and infection burden, identifying potential targets for optimising infant feeding.

bit.ly

MHRA approves world's first lower-carbon beclometasone inhalers (Clenil Modulite 100 micrograms & 200 micrograms) for patients with asthma. Uses the next generation propellant HFA-152a. 🌱 Will be available in the UK later in 2026. #Pharmsky #Respiratory www.gov.uk/government/n...

MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma

The new inhalers use a next-generation propellant designed to reduce environmental impact while maintaining the same established treatment.

gov.uk

Euan Reid@euanreid.pharmsky.app · 6mo ago

The Transition to Green Respiratory Care in NHS Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿 #Pharmsky 1/8 Respiratory prescribing in Scotland is facing its biggest shift in a generation. With NHSScotland aiming for net-zero by 2045, how we approach inhaler therapy is evolving to meet the climate emergency. 🧵